Skip to main content
Top
Published in: Medical Oncology 4/2011

01-12-2011 | Original paper

Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia

Authors: Grzegorz Helbig, Krzysztof Woźniczka, Agata Wieczorkiewicz, Jacek Pająk, Sławomira Kyrcz-Krzemien

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

Hairy cell leukaemia (HCL) is a rare, indolent lymphoproliferative disorder characterized by varying degrees of cytopenias and the presence of malignant B cells with cytoplasmic projections. Cladribine (2-chlorodeoxyadenosine, 2-CdA) is an adenosine deaminase-resistant purine analogue and has been shown to be very effective as a first-line therapeutic option for HCL. The therapy with 2-CdA is found to be well tolerated with a paucity of toxicity. The common side effects include immunosuppression and reversible myelosuppression. We report a HCL patient with A pandemic 2009-H1N1-associated pneumonia who fully recovered after oseltamivir and antibiotics. The subsequent treatment with single 5-day course of 2-CdA resulted in persistent marrow aplasia with fatal systemic aspergillosis.
Literature
1.
go back to reference Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med. 1978;89:677–82.PubMed Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med. 1978;89:677–82.PubMed
2.
go back to reference Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med. 1990;322:1117–21.PubMedCrossRef Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med. 1990;322:1117–21.PubMedCrossRef
3.
go back to reference Cheson BD. Infectious and immunosuppressive complications of purine nucleoside analog therapy. J Clin Oncol. 1995;19:2431–48. Cheson BD. Infectious and immunosuppressive complications of purine nucleoside analog therapy. J Clin Oncol. 1995;19:2431–48.
4.
go back to reference Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18:1476–81.PubMedCrossRef Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia. 2004;18:1476–81.PubMedCrossRef
5.
go back to reference Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906–11.PubMed Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906–11.PubMed
7.
go back to reference Frewin RJ, Provan D, Smith AG. Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leuekmia. Clin Lab Haem. 1997;19:151–2.CrossRef Frewin RJ, Provan D, Smith AG. Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leuekmia. Clin Lab Haem. 1997;19:151–2.CrossRef
8.
go back to reference Orchard JA, Bolam S, Oscier DG. Association of myelodysplastic changes with purine analogues. Brit J Haematol. 1998;100:677–9.CrossRef Orchard JA, Bolam S, Oscier DG. Association of myelodysplastic changes with purine analogues. Brit J Haematol. 1998;100:677–9.CrossRef
9.
go back to reference Psiachou-Leonard E, Bain BJ. Persistent bone marrow failure with dysplastic features following pentostatin therapy for hairy cell leukaemia. Clin Lab Haem. 1998;20:195–7.CrossRef Psiachou-Leonard E, Bain BJ. Persistent bone marrow failure with dysplastic features following pentostatin therapy for hairy cell leukaemia. Clin Lab Haem. 1998;20:195–7.CrossRef
10.
go back to reference Robak T, Kasznicki M, Blonski JZ, Dmoszynska A, Skotnicki A. Pure red cell aplasia in patients with chronic lymphocytic leukemia treated with cladribine. Brit J Haematol. 2001;112:1083–5.CrossRef Robak T, Kasznicki M, Blonski JZ, Dmoszynska A, Skotnicki A. Pure red cell aplasia in patients with chronic lymphocytic leukemia treated with cladribine. Brit J Haematol. 2001;112:1083–5.CrossRef
11.
go back to reference Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxysdenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241–6.PubMedCrossRef Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxysdenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106:241–6.PubMedCrossRef
12.
go back to reference Robak T, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109:3672–5.PubMedCrossRef Robak T, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109:3672–5.PubMedCrossRef
13.
go back to reference Else M, et al. Long-term follow-up of 233 patients with hairy cell leukaemia treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Brit J Haematol. 2009;145:733–40.CrossRef Else M, et al. Long-term follow-up of 233 patients with hairy cell leukaemia treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Brit J Haematol. 2009;145:733–40.CrossRef
14.
go back to reference Ellison DJ, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 1999;84:4310–5. Ellison DJ, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 1999;84:4310–5.
15.
go back to reference Gillis S, Amir G, Bennett M, Polliack A. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxydenosine. Eur J Haematol. 2001;66:7–10.PubMedCrossRef Gillis S, Amir G, Bennett M, Polliack A. Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxydenosine. Eur J Haematol. 2001;66:7–10.PubMedCrossRef
16.
go back to reference Launes C, et al. Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia. Brit J Haematol. 2010;149:874–8.CrossRef Launes C, et al. Pandemic influenza A (2009 H1N1) in children with acute lymphoblastic leukaemia. Brit J Haematol. 2010;149:874–8.CrossRef
17.
go back to reference Kharfan-Dabaja MA, et al. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol. 2010;91:124–7.PubMedCrossRef Kharfan-Dabaja MA, et al. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol. 2010;91:124–7.PubMedCrossRef
18.
go back to reference Benz R, Siciliano RD, Stusi G, Fehr J. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol. 2009;82:194–200.PubMedCrossRef Benz R, Siciliano RD, Stusi G, Fehr J. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol. 2009;82:194–200.PubMedCrossRef
Metadata
Title
Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia
Authors
Grzegorz Helbig
Krzysztof Woźniczka
Agata Wieczorkiewicz
Jacek Pająk
Sławomira Kyrcz-Krzemien
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9626-9

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.